Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG (Nasdaq: CRSP) files detailed reports with the U.S. Securities and Exchange Commission that document its financial condition, clinical pipeline progress, collaborations, and capital markets activity. On this SEC filings page, Stock Titan aggregates CRSP’s regulatory documents and pairs them with AI-powered summaries to help readers interpret the implications of each filing.
For a gene editing biopharmaceutical company like CRISPR Therapeutics, annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe the status of programs such as CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, in vivo liver editing candidates like CTX310 and CTX320, SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, zugo-cel in autoimmune and oncology indications, and siRNA collaborations such as SRSD107/CTX611 with Sirius Therapeutics. These reports also outline risk factors, research and development priorities, and collaboration structures with partners including Vertex Pharmaceuticals.
Current reports on Form 8-K provide more focused updates on material events, such as quarterly financial results, business updates, and capital-raising actions. For example, recent 8-K filings describe the announcement of quarterly results and the use of an at-the-market equity program under an Open Market Sale Agreement with Jefferies to offer additional common shares under a shelf registration statement.
Investors can also use this page to monitor registration statements, prospectus supplements, and other offering-related filings that detail how CRISPR Therapeutics issues new equity, as well as any proxy materials that address governance and shareholder matters. Stock Titan’s tools surface new CRSP filings in near real time from EDGAR and apply AI-generated highlights so readers can quickly locate key disclosures on clinical data, collaboration terms, cash runway, and share issuance without reading every page.
CRISPR Therapeutics Chief Executive Officer and director Samarth Kulkarni reported multiple open-market sales of common shares under a pre-set Rule 10b5-1 trading plan adopted on August 27, 2025. On January 20, 2026, he sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23. Following these transactions, Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.
CRISPR Therapeutics-related Form 144 shows planned insider share sales. Dr. Samarth Kulkarni has filed notice to sell 60,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $3,648,600. The filing notes that 48,081 shares were acquired on 10/16/2025 and 11,919 shares on 08/15/2025, both as restricted stock awards from the issuer, treated as compensation. It also discloses that during the past three months, Dr. Kulkarni sold 30,000 common shares on 01/20/2026 for gross proceeds of $1,552,593. Shares of the issuer’s common stock outstanding are listed as 95,300,233.
A shareholder filed a Rule 144 notice to sell 34,972 shares of common stock through Morgan Stanley Smith Barney on or about January 22, 2026 on NASDAQ. The planned sale has an aggregate market value of $2,105,069.60.
The shares to be sold were acquired on January 22, 2026 via a stock option exercise, paid for in cash. Shares of the issuer outstanding were 95,300,233 at the time of the notice; this is a baseline figure, not the amount being sold.
Over the prior three months, the same seller, Raju Prasad, reported additional common share sales of 10,000 shares for $559,548.00 on December 22, 2025 and 29,700 shares for $1,786,635.87 on January 6, 2026.
A holder of common stock in CRSP has filed a notice of proposed resale under Rule 144. The filing covers the planned sale of 30,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $1,578,300. The shares are part of a larger base of 95,300,233 common shares outstanding.
The securities to be sold were acquired as compensation through restricted stock awards from the issuer in multiple grants dated between 2018 and 2025, each labeled as compensation on the acquisition and payment dates. The person for whose account the sale is to be made represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
CRISPR Therapeutics AG filed an update on multiple gene-editing programs across cardiovascular, autoimmune, oncology and regenerative medicine. The company highlighted continued progress with its in vivo programs using a proprietary lipid nanoparticle delivery platform, including CTX310, which in 2025 showed deep and durable reductions in triglycerides and LDL after a single intravenous dose with a well‑tolerated safety profile and has moved into Phase 1b trials.
CTX320, targeting LPA, has shown reductions of up to 73% in a dose‑escalation trial, while next‑generation candidate CTX321 with about two‑fold greater preclinical potency is in IND/CTA‑enabling studies. Additional preclinical assets include CTX460 for alpha‑1 antitrypsin deficiency and CTX340 for refractory hypertension. Zugocabtagene geleucel (zugo‑cel) is in Phase 1 autoimmune trials where early systemic lupus erythematosus patients achieved drug‑free remission or full score improvement, and an oncology trial is ongoing alongside a new collaboration with Eli Lilly. In regenerative medicine for diabetes, CTX211 data with detectable C‑peptide at 12 months support a move to next‑generation candidate CTX213.
CRISPR Therapeutics AG’s Chief Financial Officer, Prasad Raju, reported option exercises and share sales in Common Shares. On January 6, 2026, he exercised stock options to acquire 23,361 Common Shares at an exercise price of $45.15 and another 6,339 Common Shares at $44.31. After these transactions, he directly held 30,128 and 36,467 Common Shares, respectively, from the two exercises.
The same day, he reported open-market sales of Common Shares in multiple transactions, including 18,933 shares at a weighted average price of $60.1799 and additional sales at weighted average prices of $60.00 and $60.2134, leaving him with 6,767 Common Shares directly held after the final sale. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 18, 2025. The derivative table shows remaining stock options outstanding with expirations in 2033 and vesting schedules described in the footnotes.
Raju Prasad filed a notice of proposed sale of the issuer’s common stock under Rule 144. The planned transaction covers 29,700 common shares, to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,786,635.87, based on information in the filing. The shares relate to a stock option exercise on 01/06/2026, paid in cash the same day, and are expected to be sold around 01/06/2026 on the NASDAQ market, where 95,300,233 shares of this class are outstanding.
The filing also reports that over the prior three months, Prasad sold 10,000 common shares on 12/22/2025 for $559,548.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
CRISPR Therapeutics AG’s Chief Financial Officer, who files individually, reported automatic sales of company stock. On December 22, 2025, the officer sold a total of 10,000 common shares of CRISPR Therapeutics AG in three separate transactions, at weighted average prices of $55.1022, $56.3345, and $56.8858 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, which is designed to provide an affirmative defense for insiders trading under predetermined instructions. After these sales, the officer beneficially owns 6,767 common shares directly.
CRISPR Therapeutics AG reported a wider quarterly loss as collaboration and R&D spending remained high. For Q3 2025, total revenue was $0.9 million from grants, while operating expenses reached $132.9 million, driven by $58.9 million in research and development and $57.1 million in collaboration expense, net. Net loss was $106.4 million (basic and diluted loss per share $1.17).
Year to date, the company recorded a $451.0 million net loss, including $96.3 million of acquired in‑process R&D tied to the Sirius collaboration. Liquidity remained strong with $286.5 million in cash and cash equivalents and $1,629.2 million in current marketable securities, plus $28.4 million non‑current. Shareholders’ equity stood at $1.916 billion. The company continued equity financing, issuing 5.1 million shares under its 2021 ATM for $286.8 million in net proceeds, and later launched a new 2025 ATM. As of September 30, 2025, 93,872,794 common shares were outstanding.
CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025. The company provided the full details in a press release attached as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, and therefore are not subject to Section 18 liabilities or incorporated by reference except as specifically stated. The 8‑K was signed by CEO Samarth Kulkarni, Ph.D., on November 10, 2025.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
